FDA Warning Letters Hit Three Repackers For Failing To Identify Original API Makers
Executive Summary
The US FDA’s concerns about the transparency of the pharmaceutical supply chain surfaced in three recent drug GMP warning letters to drug repackers of active pharmaceutical ingredients who failed to disclose the names of the API manufacturers to their customers. Janet Woodcock, director of the agency's drug center, called such lack of transparency a "real threat" to public health that must be addressed quickly.
You may also be interested in...
Data Integrity Remains Challenging For API Manufacturers
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
US FDA Says Data Integrity Remains Challenging For API Manufacturers
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
First-Time OTC Facility Inspections Drove US FDA Warning Letter Surge In FY 2019
The good news: 75% of firms not previously inspected were in compliance with US drug GMP requirements; the bad news, 25% weren't. CDER Office of Manufacturing Quality director Francis Godwin says FDA remains concerned about vulnerabilities in supply chain when OTC firms don't test products for impurities that have harmed and killed consumers in the past.